Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

"EuroVacc 02" HIV Vaccine trial begins

16.02.2005


The European Vaccine Effort against HIV/AIDS, today announced that a phase I clinical trial of novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV infection has started in Lausanne and London in February 2005. These vaccines are based on HIV subtype C, which is prevalent in China, India and sub-Saharan Africa, and constitutes more than 50 percent of the new HIV infections worldwide.



The phase I clinical trial, with the EuroVacc Foundation as the sponsor, will evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection. The study will recruit 40 healthy volunteers: 20 at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, and 20 at St Mary’s Hospital, Imperial College London. All volunteers, male or female, should be between 18 and 55 yrs, HIV-negative and at low risk of infection.

The trial will carefully evaluate the safety and immunogenicity of the combination of the vaccines, in particular their ability to generate HIV-specific cell-mediated immune response to HIV, which is considered to be a key determinant of protection against infection. According to the principal clinical investigators Prof. Giuseppe Pantaleo of CHUV in Lausanne and Prof. Jonathan Weber of Imperial College London for the clinical studies, “if this study generates promising results, EuroVacc intends to further evaluate the vaccines in larger clinical trials.”


Development background

The vaccine candidates for the trial - DNA-HIV-C and NYVAC-HIV-C - were developed within the network European Vaccine Effort against HIV/AIDS. NYVAC-HIV-C (a vaccine candidate based on poxvirus) was manufactured by sanofi pasteur - the vaccine division of Sanofi-Aventis - and has already been evaluated in a phase I study (EuroVacc 01) at the same clinical centres in Lausanne and London. The completed phase I study showed that the NYVAC-HIV-C is safe and immunogenic. The DNA-HIV-C vaccine was developed by Professors Hans Wolf and Ralf Wagner at the University of Regensburg based on a representative Chinese subtype C isolate CN54 jointly developed with Professor Yiming Shao from the CDC Beijing. The plasmid was constructed in collaboration with Geneart GmbH - a biotech company in Regensburg Germany, and the vaccine was manufactured by Cobra Biomanufacturing Plc.

About EuroVacc

The European Vaccine Effort against HIV/AIDS network, funded by the European Union under the 5th Framework Programme, involves 21 leading research laboratories as well as pharmaceutical companies and biotech companies in France, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom. The goal of this network is to develop safe and effective preventive vaccines against HIV/AIDS. This group has been working together for more than five years, and has developed a pipeline of potential vaccines.

The EuroVacc Foundation, a non profit organization, was created in 2002 as an evolution of the network. The EuroVacc Foundation aims at facilitating European collaboration in vaccine development, coordinating European efforts and raising funds for fundamental and clinical research so as to accelerate the development of a safe and effective vaccine against HIV infection. The Foundation also promotes educational and training programmes relevant to vaccine development worldwide.

Tony Stephenson | alfa
Further information:
http://www.imperial.ac.uk

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

DGIST develops 20 times faster biosensor

24.04.2017 | Physics and Astronomy

Nanoimprinted hyperlens array: Paving the way for practical super-resolution imaging

24.04.2017 | Materials Sciences

Atomic-level motion may drive bacteria's ability to evade immune system defenses

24.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>